<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00482755</url>
  </required_header>
  <id_info>
    <org_study_id>MA29</org_study_id>
    <secondary_id>CAN-NCIC-MA29</secondary_id>
    <secondary_id>PFIZER-CAN-NCIC-MA29</secondary_id>
    <secondary_id>CDR0000547161</secondary_id>
    <nct_id>NCT00482755</nct_id>
  </id_info>
  <brief_title>Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before&#xD;
      surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be&#xD;
      removed.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with&#xD;
      newly diagnosed stage II or stage IIIA breast cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility of neoadjuvant sunitinib malate in patients with newly&#xD;
           diagnosed, resectable stage II-IIIA breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the nature, severity, and frequency of adverse events in patients treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the response rate in patients treated with this drug.&#xD;
&#xD;
        -  Evaluate markers of angiogenesis (e.g., VEGF receptor, platelet-derived growth factor&#xD;
           receptor, circulating plasma VEGF, sVEGFR-2, sVEGFR-3, sKIT, and tumor vascularity) both&#xD;
           pre- and post-treatment.&#xD;
&#xD;
        -  Examine the role of both host- and tumor-specific genes pertaining to response and&#xD;
           toxicity.&#xD;
&#xD;
        -  Compare tumor vascular parameters pre- and post-treatment using DCE-MRI.&#xD;
&#xD;
        -  Compare cell death and tumor microcirculation pre- and post-treatment using&#xD;
           contrast-enhanced spectroscopic and microbubble contrast-enhanced ultrasound.&#xD;
&#xD;
        -  Compare tumor metabolic activity pre- and post-treatment using fludeoxyglucose F 18-PET.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive oral sunitinib malate once daily for 14-21 days in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Tissue samples are obtained by needle biopsy at baseline and once between days 14-21. Blood&#xD;
      samples are collected at baseline, once between days 14-21, and at 4 weeks post-treatment for&#xD;
      pharmacodynamic and other studies. Markers of angiogenesis (VEGF receptors, platelet-derived&#xD;
      growth factor receptor, VEGF, sKIT, and tumor vascularity) are detected by&#xD;
      immunohistochemistry. DCE-MRI and fludeoxyglucose F 18-PET are conducted for research studies&#xD;
      at baseline and once between days 14-21.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 4 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2007</start_date>
  <completion_date type="Actual">January 18, 2011</completion_date>
  <primary_completion_date type="Actual">January 20, 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nature, severity, and frequency of adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity (response rate)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of angiogenesis pre- and post-treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of both host- and tumor-specific genes pertaining to response and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of tumor vascular parameters pre- and post-treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of cell death and tumor microcirculation pre- and post-treatment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of tumor metabolic activity pre- and post-treatment</measure>
  </secondary_outcome>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>needle biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Newly diagnosed disease&#xD;
&#xD;
               -  Stage II-IIIA (T1c, T2, or T3) disease&#xD;
&#xD;
               -  Unifocal disease&#xD;
&#xD;
               -  Resectable disease&#xD;
&#xD;
          -  Tumor must be suitable for multiple biopsies and imaging&#xD;
&#xD;
          -  No prior breast cancer&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Male or female&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Calcium ≤ 3 mmol/L&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancies except adequately treated nonmelanoma skin cancer, curatively&#xD;
             treated in situ cancer of the cervix, or other solid tumors curatively treated with no&#xD;
             evidence of disease for ≥ 5 years&#xD;
&#xD;
          -  No QTc prolongation (defined as a QTc interval ≥ 500 msec) or other significant ECG&#xD;
             abnormalities&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular&#xD;
             fibrillation ≥ 3 beats in a row)&#xD;
&#xD;
          -  No prior or concurrent NYHA class II-IV cardiovascular disease&#xD;
&#xD;
          -  No inadequately controlled hypertension (systolic BP ≥ 140 mm Hg or diastolic BP ≥ 90&#xD;
             mm Hg)&#xD;
&#xD;
          -  No myocardial infarction, cardiac arrhythmia, stable or unstable angina, symptomatic&#xD;
             congestive heart failure, or coronary/peripheral artery bypass graft or stenting&#xD;
             within the past 12 months&#xD;
&#xD;
          -  No pulmonary embolism within the past 12 months&#xD;
&#xD;
          -  No cerebrovascular accident or transient ischemic attack within the past 12 months&#xD;
&#xD;
          -  No serious illness or medical condition that would preclude study compliance&#xD;
             including, but not limited to, the following:&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorder&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Serious or nonhealing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No medical condition that could interfere with oral medication intake (e.g., frequent&#xD;
             vomiting, malabsorption)&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds with similar chemical&#xD;
             composition to sunitinib malate&#xD;
&#xD;
          -  No preexisting hypothyroidism unless patient is euthyroid on medication&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 7 days since prior and no concurrent CYP3A4 inhibitors, including the&#xD;
             following:&#xD;
&#xD;
               -  Azole antifungals (ketoconazole, miconazole)&#xD;
&#xD;
               -  Verapamil&#xD;
&#xD;
               -  Clarithromycin&#xD;
&#xD;
               -  HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir,&#xD;
                  nelfinavir)&#xD;
&#xD;
               -  Erythromycin&#xD;
&#xD;
               -  Delavirdine&#xD;
&#xD;
               -  Diltiazem&#xD;
&#xD;
          -  At least 12 days since prior and no concurrent CYP3A4 inducers, including the&#xD;
             following:&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Rifabutin&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Efavirenz&#xD;
&#xD;
               -  Pentobarbital&#xD;
&#xD;
               -  Tipranavir&#xD;
&#xD;
               -  Phenobarbital&#xD;
&#xD;
          -  No prior protein tyrosine kinase inhibitor&#xD;
&#xD;
          -  No prior antiangiogenic agent&#xD;
&#xD;
          -  No prior hormonal therapy, radiotherapy, chemotherapy, surgery, investigational&#xD;
             therapy, or other therapy for breast cancer&#xD;
&#xD;
          -  At least 12 days since prior and no concurrent cyclooxygenase-2 inhibitors (e.g.,&#xD;
             etoricoxib, valdecoxib, celecoxib, dual cyclooxygenase/lipid oxidation, and&#xD;
             lumiracoxib)&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent agents with proarrhythmic potential (e.g., terfenadine, quinidine,&#xD;
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone,&#xD;
             indapamide, and flecainide)&#xD;
&#xD;
          -  No other concurrent treatment for breast cancer&#xD;
&#xD;
          -  No concurrent coumadin-derivative anticoagulants (e.g., warfarin)&#xD;
&#xD;
               -  Anticoagulants at ≤ 2 mg/day for prophylaxis of thrombosis allowed&#xD;
&#xD;
               -  Low molecular weight heparin allowed provided INR ≤ 1.5&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maureen E. Trudeau, BSc, MA, MD, FRCPC</last_name>
    <role>Study Chair</role>
    <affiliation>Toronto Sunnybrook Regional Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edmond Odette Cancer Centre at Sunnybrook</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 4, 2007</study_first_submitted>
  <study_first_submitted_qc>June 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2007</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>male breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

